A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Inclusion Criteria:

- Willing and able to provide written informed consent for the trial

- ≥ 18 years of age

- Histologically- or cytologically- confirmed locally advanced or metastatic WDNET

- SSA therapy is recommended by physician for disease management, and has not yet begun

- ECOG performance status of 0, 1, or 2

Exclusion Criteria:

- Currently participating in a study of an investigational agent

- Prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study Day
1 or not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a
previously administered agent

*Note: Subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to
this criterion and may qualify for the study

- No concurrent chemotherapy or targeted small molecule therapy

- If received major surgery, not recovered adequately from the toxicity and/or
complications from the intervention prior to starting the study

- Known additional malignancy that is progressing or requires active treatment

- Active infection requiring systemic therapy

- Known psychiatric or substance abuse disorders that would interfere with cooperation
with the requirements of the trial